Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS) : a multicentre, open-label, randomised, phase 3 trial

Dummer, Reinhard; Ascierto, Paolo A.; Gogas, Helen J.; Arance, Ana; Mandala, Mario; Liszkay, Gabriella; Garbe, Claus; Schadendorf, Dirk; Krajsova, Ivana; Gutzmer, Ralf; Sileni, Vanna Chiarion; Dutriaux, Caroline; de Groot, Jan Willem B.; Yamazaki, Naoya; Loquai, Carmen; Moutouh-de Parseval, Laure A.; Pickard, Michael D.; Sandor, Victor; Roberti, Caroline; Flaherty, Keith T.

Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS) : a multicentre, open-label, randomised, phase 3 trial

Author:

Dummer, Reinhard; Ascierto, Paolo A.; Gogas, Helen J.; Arance, Ana; Mandala, Mario; Liszkay, Gabriella; Garbe, Claus; Schadendorf, Dirk; Krajsova, Ivana; Gutzmer, Ralf; Sileni, Vanna Chiarion; Dutriaux, Caroline; de Groot, Jan Willem B.; Yamazaki, Naoya; Loquai, Carmen; Moutouh-de Parseval, Laure A.; Pickard, Michael D.; Sandor, Victor; Roberti, Caroline; Flaherty, Keith T.

Tübinger Autor(en):

Garbe, Claus

Published in:

Lancet Oncology (2018), Bd. 19, H. 10, S. 1315-1327

Verlagsangabe:

Elsevier Science Inc

Language:

English

Full text:

http://dx.doi.org/10.1016/S1470-2045(18)30497-2

ISSN:

1474-5488